细胞程序性死亡受体1信号通路在肿瘤免疫疗法中的应用

摘要

肿瘤免疫疗法研究在肿瘤治疗领域取得了突破性的进展.程序性死亡受体1(programmed cell death receptor 1,PD-1)主要表达于T淋巴细胞表面,是一种重要的免疫调节蛋白.PD-1及其配体PD-L1相互作用参与肿瘤诱导的免疫抑制效应.针对PD-1/PD-L1信号通路的抗体药物在临床应用中呈现出显著性的疗效.%Research in immunotherapy has achieved important progress in tumor treatment. Programmed cell death receptor 1(PD-1) is mainly expressed on the T lymphocyte surface and serves as an important immune regu-lator. The interactions of PD-1 and its ligand, PD-L1 are involved in tumor-induced immunosuppression. Some of the approved antibody preparations targeting PD-1/PD-L1 signaling showed significant clinical benefits.